Eurofins Optimed is a French Contract Research Organization (CRO) and Clinical Pharmacology Unit specialized in early‑phase clinical development. With more than 35 years of experience, the company supports pharmaceutical, biotechnology and medical device developers in the design, execution and management of Phase I and Phase II clinical trials in healthy volunteers and patients. Operating from its dedicated clinical facility in Gières, France, Eurofins Optimed combines scientific rigor, regulatory expertise and operational excellence to accelerate the transition from preclinical research to clinical proof of concept.

This established expertise now benefits from the French Fast Track regulatory framework, enabling accelerated timelines with authorization potentially granted within 14 days in eligible cases, further enhancing the attractiveness of France. Close interactions with sponsors, investigators and regulatory authorities further contribute to efficient study initiation and execution within this robust regulatory environment.

Eurofins Optimed provides a full‑service CRO offering, covering study design, regulatory submissions, clinical operations, volunteer and patient recruitment, pharmacovigilance, data management and biometry. The organization is particularly recognized for its expertise in First‑in‑Human studies, bioequivalence, drug–drug interaction studies, food‑effect studies and QT assessment, ensuring robust and high‑quality data generation in compliance with GCP and international regulatory standards.

A key differentiator of Eurofins Optimed is its strong integration within the Eurofins Group, enabling seamless collaboration with Eurofins ADME Bioanalyses and other specialized entities. This integrated model provides sponsors with end‑to‑end solutions combining clinical research, bioanalysis, pharmacokinetics and biomarker expertise, particularly valuable for complex and innovative drug development programs. Through this comprehensive and coordinated approach, Eurofins Optimed acts as a strategic partner for companies seeking to de‑risk and optimize early clinical development.